文献速递白血病淋巴瘤

应答适应、限时维奈克拉联合厄布利妥昔单抗及乌布妥昔单抗治疗复发/难治性慢性淋巴细胞白血病

Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia.
PubMed 文献 · Blood Adv · 2024-01-01

本研究为1/2期临床试验,纳入46例复发/难治性慢性淋巴细胞白血病(CLL)和5例Richter转化患者,评估维奈克拉联合厄布利妥昔单抗及乌布妥昔单抗(U2-VeN)的疗效与安全性。CLL意向治疗总缓解率98%,可评估患者最佳缓解率100%(完全缓解42%),治疗结束时骨髓10^-4水平不可测微小残留病(uMRD)率77%(30/39)。限时联合方案安全高效,包括既往共价BTK抑制剂难治患者。

要点

  • CLL意向治疗总缓解率98%,可评估患者最佳缓解率100%(完全缓解42%)。
  • 治疗结束时骨髓10^-4 uMRD率77%(30/39),既往BTK抑制剂难治者uMRD率71%。
  • 特别关注不良事件:腹泻50%(3/4级11%),AST和/或ALT升高33%(3/4级7%)。

核心结论

  • 限时维奈克拉联合U2是复发/难治性CLL(包括既往共价BTK抑制剂治疗患者)安全且高效的联合治疗。

研究设计与样本

  • 1/2期临床试验,纳入复发/难治性CLL患者46例和Richter转化患者5例。
  • CLL患者达到不可测微小残留病(uMRD)者于12周期后停止治疗。
  • 试验注册号NCT03379051。

主要发现

  • CLL意向治疗总缓解率98%,可评估患者最佳缓解率100%,其中完全缓解42%。
  • 治疗结束时骨髓10^-4 uMRD率77%(30/39),既往BTK抑制剂难治的14例患者中uMRD率71%。
  • 特别关注不良事件:腹泻发生率50%(3/4级11%),AST和/或ALT升高15例(33%),其中3/4级3例(7%)。
  • 无维奈克拉相关肿瘤溶解综合征病例,96%患者门诊启动治疗。

临床怎么用

  • 原文结论为限时维奈克拉联合U2是复发/难治性CLL安全且高效的联合治疗,包括既往共价BTK抑制剂治疗患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Many patients with chronic lymphocytic leukemia (CLL) will develop treatment resistance to Bruton tyrosine kinase (BTK) inhibitors. Phosphatidylinositol-3-kinase (PI3K) inhibitors, including umbralisib, have significant clinical activity in relapsed/refractory CLL, but prolonged exposure is associated with potential toxicities. Owing to the synergistic antitumor effects of combined PI3K and BCL-2 inhibition, we sought to explore the feasibility of response-adapted, time-limited therapy to optimize disease control while mitigating the risks of prolonged treatment. We conducted a phase 1/2 clinical trial to determine the safety and efficacy of venetoclax in combination with umbralisib and the anti-CD20 monoclonal antibody, ublituximab, (U2-VeN) in patients with relapsed/refractory CLL (N = 46) and Richter transformation (N = 5). After 12 cycles, treatment was stopped for patients with CLL who achieved undetectable minimal residual disease (uMRD). Adverse events of special interest included diarrhea in 50% of patients (11% grade 3/4), and aspartate aminotransferase and/or alanine aminotransferase elevation in 15 patients (33%), with 3 (7%) grade 3/4. There were no cases of tumor lysis syndrome related to venetoclax, with outpatient initiation in 96% of patients. The intent-to-treat overall response rate for CLL was 98% with best response of 100% in evaluable patients (42% complete responses). The end-of-treatment rate of uMRD at 10-4 in bone marrow was 77% (30/39), including a 71% uMRD rate among 14 patients refractory to prior BTK inhibitor. Time-limited venetoclax and U2 is safe and highly effective combination therapy for patients with relapsed/refractory CLL including those who have been previously treated with covalent BTK inhibitors. This trial was registered on www.clinicaltrials.gov as #NCT03379051.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Hill BT, Ma S, Zent CS, et al. Response-adapted, time-limited venetoclax, umbralisib, and ublituximab for relapsed/refractory chronic lymphocytic leukemia. Blood Adv. 2024. PMID: 37871300. doi:10.1182/bloodadvances.2023010693

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。